These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8346730)

  • 1. Effect of sotalol on ventricular fibrillation and defibrillation in humans.
    Dorian P; Newman D
    Am J Cardiol; 1993 Aug; 72(4):72A-79A. PubMed ID: 8346730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy.
    Dorian P; Newman D; Sheahan R; Tang A; Green M; Mitchell J
    J Cardiovasc Electrophysiol; 1996 Oct; 7(10):952-61. PubMed ID: 8894937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotalol in patients with implanted automatic defibrillators: effects on defibrillation and comparison with amiodarone.
    Dorian P; Newman D; Harris L; Downar E
    Can J Cardiol; 1994 Mar; 10(2):193-200. PubMed ID: 8143220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Suchalla R; Mermi J; Dörnberger V; Seipel L
    Int J Cardiol; 1999 Jun; 69(3):271-9. PubMed ID: 10402110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: favorable effects of D, L-sotalol.
    Boriani G; Biffi M; Frabetti L; Maraschi M; Branzi A
    Heart Lung; 2000; 29(6):412-6. PubMed ID: 11080321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotalol: An important new antiarrhythmic.
    Anderson JL; Prystowsky EN
    Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
    Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of ventricular fibrillation based on monophasic action potential morphology in the human heart.
    Swartz JF; Jones JL; Fletcher RD
    Circulation; 1993 Jun; 87(6):1907-14. PubMed ID: 8504503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators.
    Stevens SK; Haffajee CI; Naccarelli GV; Schwartz KM; Luceri RM; Packer DL; Rubin AM; Kowey PR
    J Am Coll Cardiol; 1996 Aug; 28(2):418-22. PubMed ID: 8800119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency characteristics and associations with the defibrillation threshold of ventricular fibrillation in patients with implantable cardioverter defibrillators.
    Iijima K; Chinushi M; Saitoh O; Hasegawa K; Sonoda K; Yagihara N; Sato A; Izumi D; Watanabe H; Furushima H; Aizawa Y; Minamino T
    Intern Med; 2015; 54(10):1175-82. PubMed ID: 25986253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease).
    Parkash R; Nault I; Rivard L; Gula L; Essebag V; Nery P; Tung S; Raymond JM; Sterns L; Doucette S; Wells G; Tang ASL; Stevenson WG; Sapp JL
    Circ Arrhythm Electrophysiol; 2018 Jan; 11(1):e005663. PubMed ID: 29305400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
    Connolly SJ; Dorian P; Roberts RS; Gent M; Bailin S; Fain ES; Thorpe K; Champagne J; Talajic M; Coutu B; Gronefeld GC; Hohnloser SH;
    JAMA; 2006 Jan; 295(2):165-71. PubMed ID: 16403928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential proarrhythmic effect of biventricular pacing: fact or myth?
    Shukla G; Chaudhry GM; Orlov M; Hoffmeister P; Haffajee C
    Heart Rhythm; 2005 Sep; 2(9):951-6. PubMed ID: 16171749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].
    Takeichi K; Kasanuki H; Ohnishi S; Endoh Y; Hosoda S
    J Cardiol; 1996 Nov; 28(5):277-86. PubMed ID: 8953401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators.
    Lee CH; Nam GB; Park HG; Kim HY; Park KM; Kim J; Choi KJ; Kim YH
    Circ J; 2008 Jan; 72(1):102-5. PubMed ID: 18159108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold.
    Lau CP; Lok NS
    Pacing Clin Electrophysiol; 1997 Oct; 20(10 Pt 1):2442-52. PubMed ID: 9358486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.